Data-driven prognostic features of cognitive trajectories in patients with amnestic mild cognitive impairments 11 Medical and Health Sciences 1103 Clinical Sciences 17 Psychology and Cognitive Sciences 1701 Psychology

Yeo Jin Kim, Seong Kyoung Cho, Hee Jin Kim, Jin San Lee, Juyoun Lee, Young Kyoung Jang, Jacob W. Vogel, Duk L. Na, Changsoo Kim, Sang Won Seo

Research output: Contribution to journalArticle

Abstract

Background: Although amnestic mild cognitive impairment (aMCI) is generally considered to be a prodromal stage of Alzheimer's disease, patients with aMCI show heterogeneous patterns of progression. Moreover, there are few studies investigating data-driven cognitive trajectory in aMCI. We therefore classified patients with aMCI based on their cognitive trajectory, measured by clinical dementia rating sum of boxes (CDR-SOB). Then, we compared the clinical and neuroimaging features among groups classified by cognitive trajectory. Methods: We retrospectively recruited 278 patients with aMCI who underwent three or more timepoints of neuropsychological testing. They also had magnetic resonance imaging (MRI) including structured three-dimensional volume images. Cortical thickness was measured using surface-based methods. We performed trajectory analyses to classify our aMCI patients according to their progression and investigate their cognitive trajectory using CDR-SOB. Results: Trajectory analyses showed that patients with aMCI were divided into three groups: stable (61.8%), slow decliner (31.7%), and fast decliner (6.5%). Changes throughout a mean follow-up duration of 3.7 years in the CDR-SOB for the subgroups of stable/slow/fast decliners were 1.3-, 6.4-, and 12-point increases, respectively. Decliners were older and carried apolipoprotein E4 (APOE4) genotypes more frequently than stable patients. Compared with the stable group, decliners showed a higher frequency of aMCI patients with both visual and verbal memory dysfunction, late stage aMCI, and multiple domain dysfunction. In addition, compared with the stable group, the slow decliners showed cortical thinning predominantly in bilateral parietotemporal areas, while the fast decliners showed cortical thinning predominantly in bilateral frontotemporal areas. Both decliner groups showed worse cognitive function in attention, language, visuospatial, memory, and frontal/executive domains than the stable group. Conclusions: Our data-driven trajectory analysis provides new insights into heterogeneous cognitive trajectories of aMCI and further suggests that baseline clinical and neuroimaging profiles might predict aMCI patients with poor prognosis.

Original languageEnglish
Article number10
JournalAlzheimer's Research and Therapy
Volume11
Issue number1
DOIs
Publication statusPublished - 2019 Jan 22

Fingerprint

Cognitive Science
Psychology
Health
Dementia
Neuroimaging
Cognitive Dysfunction
Prodromal Symptoms
Apolipoprotein E4
Three-Dimensional Imaging
Cognition
Alzheimer Disease
Language

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

Kim, Yeo Jin ; Cho, Seong Kyoung ; Kim, Hee Jin ; Lee, Jin San ; Lee, Juyoun ; Jang, Young Kyoung ; Vogel, Jacob W. ; Na, Duk L. ; Kim, Changsoo ; Seo, Sang Won. / Data-driven prognostic features of cognitive trajectories in patients with amnestic mild cognitive impairments 11 Medical and Health Sciences 1103 Clinical Sciences 17 Psychology and Cognitive Sciences 1701 Psychology. In: Alzheimer's Research and Therapy. 2019 ; Vol. 11, No. 1.
@article{e334d3c43b2741a9b7cd553c0fe1dc8c,
title = "Data-driven prognostic features of cognitive trajectories in patients with amnestic mild cognitive impairments 11 Medical and Health Sciences 1103 Clinical Sciences 17 Psychology and Cognitive Sciences 1701 Psychology",
abstract = "Background: Although amnestic mild cognitive impairment (aMCI) is generally considered to be a prodromal stage of Alzheimer's disease, patients with aMCI show heterogeneous patterns of progression. Moreover, there are few studies investigating data-driven cognitive trajectory in aMCI. We therefore classified patients with aMCI based on their cognitive trajectory, measured by clinical dementia rating sum of boxes (CDR-SOB). Then, we compared the clinical and neuroimaging features among groups classified by cognitive trajectory. Methods: We retrospectively recruited 278 patients with aMCI who underwent three or more timepoints of neuropsychological testing. They also had magnetic resonance imaging (MRI) including structured three-dimensional volume images. Cortical thickness was measured using surface-based methods. We performed trajectory analyses to classify our aMCI patients according to their progression and investigate their cognitive trajectory using CDR-SOB. Results: Trajectory analyses showed that patients with aMCI were divided into three groups: stable (61.8{\%}), slow decliner (31.7{\%}), and fast decliner (6.5{\%}). Changes throughout a mean follow-up duration of 3.7 years in the CDR-SOB for the subgroups of stable/slow/fast decliners were 1.3-, 6.4-, and 12-point increases, respectively. Decliners were older and carried apolipoprotein E4 (APOE4) genotypes more frequently than stable patients. Compared with the stable group, decliners showed a higher frequency of aMCI patients with both visual and verbal memory dysfunction, late stage aMCI, and multiple domain dysfunction. In addition, compared with the stable group, the slow decliners showed cortical thinning predominantly in bilateral parietotemporal areas, while the fast decliners showed cortical thinning predominantly in bilateral frontotemporal areas. Both decliner groups showed worse cognitive function in attention, language, visuospatial, memory, and frontal/executive domains than the stable group. Conclusions: Our data-driven trajectory analysis provides new insights into heterogeneous cognitive trajectories of aMCI and further suggests that baseline clinical and neuroimaging profiles might predict aMCI patients with poor prognosis.",
author = "Kim, {Yeo Jin} and Cho, {Seong Kyoung} and Kim, {Hee Jin} and Lee, {Jin San} and Juyoun Lee and Jang, {Young Kyoung} and Vogel, {Jacob W.} and Na, {Duk L.} and Changsoo Kim and Seo, {Sang Won}",
year = "2019",
month = "1",
day = "22",
doi = "10.1186/s13195-018-0462-z",
language = "English",
volume = "11",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",

}

Data-driven prognostic features of cognitive trajectories in patients with amnestic mild cognitive impairments 11 Medical and Health Sciences 1103 Clinical Sciences 17 Psychology and Cognitive Sciences 1701 Psychology. / Kim, Yeo Jin; Cho, Seong Kyoung; Kim, Hee Jin; Lee, Jin San; Lee, Juyoun; Jang, Young Kyoung; Vogel, Jacob W.; Na, Duk L.; Kim, Changsoo; Seo, Sang Won.

In: Alzheimer's Research and Therapy, Vol. 11, No. 1, 10, 22.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Data-driven prognostic features of cognitive trajectories in patients with amnestic mild cognitive impairments 11 Medical and Health Sciences 1103 Clinical Sciences 17 Psychology and Cognitive Sciences 1701 Psychology

AU - Kim, Yeo Jin

AU - Cho, Seong Kyoung

AU - Kim, Hee Jin

AU - Lee, Jin San

AU - Lee, Juyoun

AU - Jang, Young Kyoung

AU - Vogel, Jacob W.

AU - Na, Duk L.

AU - Kim, Changsoo

AU - Seo, Sang Won

PY - 2019/1/22

Y1 - 2019/1/22

N2 - Background: Although amnestic mild cognitive impairment (aMCI) is generally considered to be a prodromal stage of Alzheimer's disease, patients with aMCI show heterogeneous patterns of progression. Moreover, there are few studies investigating data-driven cognitive trajectory in aMCI. We therefore classified patients with aMCI based on their cognitive trajectory, measured by clinical dementia rating sum of boxes (CDR-SOB). Then, we compared the clinical and neuroimaging features among groups classified by cognitive trajectory. Methods: We retrospectively recruited 278 patients with aMCI who underwent three or more timepoints of neuropsychological testing. They also had magnetic resonance imaging (MRI) including structured three-dimensional volume images. Cortical thickness was measured using surface-based methods. We performed trajectory analyses to classify our aMCI patients according to their progression and investigate their cognitive trajectory using CDR-SOB. Results: Trajectory analyses showed that patients with aMCI were divided into three groups: stable (61.8%), slow decliner (31.7%), and fast decliner (6.5%). Changes throughout a mean follow-up duration of 3.7 years in the CDR-SOB for the subgroups of stable/slow/fast decliners were 1.3-, 6.4-, and 12-point increases, respectively. Decliners were older and carried apolipoprotein E4 (APOE4) genotypes more frequently than stable patients. Compared with the stable group, decliners showed a higher frequency of aMCI patients with both visual and verbal memory dysfunction, late stage aMCI, and multiple domain dysfunction. In addition, compared with the stable group, the slow decliners showed cortical thinning predominantly in bilateral parietotemporal areas, while the fast decliners showed cortical thinning predominantly in bilateral frontotemporal areas. Both decliner groups showed worse cognitive function in attention, language, visuospatial, memory, and frontal/executive domains than the stable group. Conclusions: Our data-driven trajectory analysis provides new insights into heterogeneous cognitive trajectories of aMCI and further suggests that baseline clinical and neuroimaging profiles might predict aMCI patients with poor prognosis.

AB - Background: Although amnestic mild cognitive impairment (aMCI) is generally considered to be a prodromal stage of Alzheimer's disease, patients with aMCI show heterogeneous patterns of progression. Moreover, there are few studies investigating data-driven cognitive trajectory in aMCI. We therefore classified patients with aMCI based on their cognitive trajectory, measured by clinical dementia rating sum of boxes (CDR-SOB). Then, we compared the clinical and neuroimaging features among groups classified by cognitive trajectory. Methods: We retrospectively recruited 278 patients with aMCI who underwent three or more timepoints of neuropsychological testing. They also had magnetic resonance imaging (MRI) including structured three-dimensional volume images. Cortical thickness was measured using surface-based methods. We performed trajectory analyses to classify our aMCI patients according to their progression and investigate their cognitive trajectory using CDR-SOB. Results: Trajectory analyses showed that patients with aMCI were divided into three groups: stable (61.8%), slow decliner (31.7%), and fast decliner (6.5%). Changes throughout a mean follow-up duration of 3.7 years in the CDR-SOB for the subgroups of stable/slow/fast decliners were 1.3-, 6.4-, and 12-point increases, respectively. Decliners were older and carried apolipoprotein E4 (APOE4) genotypes more frequently than stable patients. Compared with the stable group, decliners showed a higher frequency of aMCI patients with both visual and verbal memory dysfunction, late stage aMCI, and multiple domain dysfunction. In addition, compared with the stable group, the slow decliners showed cortical thinning predominantly in bilateral parietotemporal areas, while the fast decliners showed cortical thinning predominantly in bilateral frontotemporal areas. Both decliner groups showed worse cognitive function in attention, language, visuospatial, memory, and frontal/executive domains than the stable group. Conclusions: Our data-driven trajectory analysis provides new insights into heterogeneous cognitive trajectories of aMCI and further suggests that baseline clinical and neuroimaging profiles might predict aMCI patients with poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=85060401829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060401829&partnerID=8YFLogxK

U2 - 10.1186/s13195-018-0462-z

DO - 10.1186/s13195-018-0462-z

M3 - Article

C2 - 30670089

AN - SCOPUS:85060401829

VL - 11

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

SN - 1758-9193

IS - 1

M1 - 10

ER -